A leader in precision prevention for neurodegenerative diseases, AC Immune has secured a $4.0M grant to further its clinical-stage biopharmaceutical efforts.
The company, which leverages its proprietary SupraAntigen® and Morphomer® technology platforms, is developing a broad pipeline of sixteen therapeutic and diagnostic programs targeting conditions like Alzheimer’s and Parkinson’s disease. This latest capital infusion supports AC Immune's ongoing work, with five programs currently in Phase 2 development and one in Phase 3.














